| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Endocrinologie moléculaire et cellulaire des cancers (U 540), Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France; Departments of 2 Pathology and 3 Biostatistics, Cancer Center Val d’Aurelle, Montpellier, France; and 4 Department of Medical Nutrition and Biosciences, Karolinska Institute, Novum, Huddinge, Sweden
The antiestrogen tamoxifen, a major endocrine therapy of estrogen receptor (ER)-positive breast cancer, is nevertheless inefficient in 30 to 40% of cases for unknown reasons. We retrospectively studied 50 ER-positive primary breast carcinomas. All of the patients had received tamoxifen as the only adjuvant therapy. They were divided into two groups depending on whether they relapsed within 5 years (16 tamoxifen-resistant cases) or did not relapse within 5 years (34 tamoxifen-sensitive cases). The expression of total ERß protein, and of ERßcx protein, was estimated anonymously in formalin-fixed, paraffin-embedded tumor sections, by using specific antibodies and quantifiying nuclear immunostaining with a computer image analyzer. All of the tumors were found to be HER-2/neu-negative by immunohistochemistry.
Univariate analysis showed that Scarff-Bloom-Richardsson grade modified by Elston (SBR grade; P < 0.001), tumor size (P = 0.042), and MIB-1 proliferation index (P = 0.02) were significantly higher in tamoxifen-resistant tumors. A low level of total ERß, whether in percentage of positive cells or in quantitative immunocytochemical (QIC) score, was also associated with tamoxifen resistance (P = 0.004). ERßcx expression and lymph node status were similar between the two groups. The expression of ERß in the total population was positively correlated with ERßcx (r = 0.63, P < 0.001), and was independent of the other parameters. In a multivariate analysis, ERß expression was the most important variable (P = 0.001), followed by SBR grade (I+II versus III; P = 0.008), and MIB-1 (P = 0.016).
To conclude, tamoxifen resistance is associated with classical variables of aggressive tumors (high SBR grade, proliferation index, and tumor size) but not with node invasiveness. Low ERß level is an additional independent marker, better than ER
level, to predict tamoxifen resistance.
This article has been cited by other articles:
|
|
 |
|
  A. M. Shaaban, A. R. Green, S. Karthik, Y. Alizadeh, T. A. Hughes, L. Harkins, I. O. Ellis, J. F. Robertson, E. C. Paish, P. T.K. Saunders, et al. Nuclear and Cytoplasmic Expression of ER{beta}1, ER{beta}2, and ER{beta}5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients Clin. Cancer Res., August 15, 2008; 14(16): 5228 - 5235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Honma, R. Horii, T. Iwase, S. Saji, M. Younes, K. Takubo, M. Matsuura, Y. Ito, F. Akiyama, and G. Sakamoto Clinical Importance of Estrogen Receptor-{beta} Evaluation in Breast Cancer Patients Treated With Adjuvant Tamoxifen Therapy J. Clin. Oncol., August 1, 2008; 26(22): 3727 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sugiura, T. Toyama, Y. Hara, Z. Zhang, S. Kobayashi, Y. Fujii, H. Iwase, and H. Yamashita Expression of Estrogen Receptor Wild-type and its Variant ER cx/ 2 is Correlated with Better Prognosis in Breast Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 820 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Gruvberger-Saal, P.-O. Bendahl, L. H. Saal, M. Laakso, C. Hegardt, P. Eden, C. Peterson, P. Malmstrom, J. Isola, A. Borg, et al. Estrogen Receptor {beta} Expression Is Associated with Tamoxifen Response in ER{alpha}-Negative Breast Carcinoma Clin. Cancer Res., April 1, 2007; 13(7): 1987 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Harris Estrogen Receptor-{beta}: Recent Lessons from in Vivo Studies Mol. Endocrinol., January 1, 2007; 21(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Riggs, N. S. Wickramasinghe, R. K. Cochrum, M. B. Watts, and C. M. Klinge Decreased Chicken Ovalbumin Upstream Promoter Transcription Factor II Expression in Tamoxifen-Resistant Breast Cancer Cells. Cancer Res., October 15, 2006; 66(20): 10188 - 10198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Duong, S. Elliott, D. E. Frigo, L. I. Melnik, L. Vanhoy, S. Tomchuck, H. P. Lebeau, O. David, B. S. Beckman, J. Alam, et al. AKT Regulation of Estrogen Receptor {beta} Transcriptional Activity in Breast Cancer. Cancer Res., September 1, 2006; 66(17): 8373 - 8381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C Murphy and P. H Watson Is oestrogen receptor- {beta} a predictor of endocrine therapy responsiveness in human breast cancer? Endocr. Relat. Cancer, June 1, 2006; 13(2): 327 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Savinov, A. G. Remacle, V. S. Golubkov, M. Krajewska, S. Kennedy, M. J. Duffy, D. V. Rozanov, S. Krajewski, and A. Y. Strongin Matrix Metalloproteinase 26 Proteolysis of the NH2-Terminal Domain of the Estrogen Receptor {beta} Correlates with the Survival of Breast Cancer Patients. Cancer Res., March 1, 2006; 66(5): 2716 - 2724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Rody, U Holtrich, C Solbach, K Kourtis, G von Minckwitz, K Engels, S Kissler, R Gatje, T Karn, and M Kaufmann Methylation of estrogen receptor {beta} promoter correlates with loss of ER-{beta} expression in mammary carcinoma and is an early indication marker in premalignant lesions Endocr. Relat. Cancer, December 1, 2005; 12(4): 903 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Shaaban, V. Speirs, H. Rochefort, and M. Esslimani-Sahla The Estrogen Receptors {alpha}, {beta}, and {beta}cx Clin. Cancer Res., November 15, 2005; 11(22): 8222 - 8223. [Full Text] [PDF]
|
|
|
|
|
|
M. Esslimani-Sahla, A. Kramar, J. Simony-Lafontaine, M. Warner, J.-A. Gustafsson, and H. Rochefort Increased Estrogen Receptor {beta}cx Expression during Mammary Carcinogenesis Clin. Cancer Res., May 1, 2005; 11(9): 3170 - 3174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L C Murphy, B Peng, A Lewis, J R Davie, E Leygue, A Kemp, K Ung, M Vendetti, and R Shiu Inducible upregulation of oestrogen receptor-{beta}1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells J. Mol. Endocrinol., April 1, 2005; 34(2): 553 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy Predictive Markers in Breast and Other Cancers: A Review Clin. Chem., March 1, 2005; 51(3): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
